Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding is in a good position for growth with their pipeline candidates, including apitegromab and SRK-439. The recent regulatory interactions and updates, along with the company's preparations for launch upon approval, indicate that the manufacturing setbacks have been resolved and the focus can shift back to the drug's efficacy and potential in treating SMA. Additionally, clearance from the FDA for the BLA resubmission and a CHMP meeting for apitegromab's MAA in Europe reinforce the company's potential for success. However, there are some risks to consider, such as competition and the possibility of the drugs not showing sufficient efficacy. Overall, the positive outlook for Scholar Rock Holding is supported by strong clinical data and potential for growth in the rare neuromuscular disease market.

Bears say

Scholar Rock Holding is currently experiencing significant delays in the launch of their potential SMA treatment, apitegromab, due to regulatory issues with their manufacturing facility. This delay introduces uncertainty and variability into the timeline and could potentially hurt the company's growth prospects and long-term valuation. Additionally, the company's success relies heavily on the expansion of their pipeline beyond SMA, and any further issues with Apitegromab's launch could hinder these efforts.

SRRK has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 13 analysts, SRRK has a Buy consensus rating as of Jul 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.